Review decision date: December 2014
Following the recent surveillance review which checks the need to update CG157, this guideline should not be updated at this time. This guideline will be checked again for update at its scheduled time point according to the methods described here
Next review date: June 2017
This clinical guideline offers best practice advice on the care of adults, children and young people with stage 4 or 5 chronic kidney disease (CKD) who have, or are at risk of, hyperphosphataemia.
People with stage 4 or 5 CKD often have high levels of phosphate in their blood; this is called hyperphosphataemia. When the kidneys are not working as well as they should, phosphate is not passed out of the body in the urine. Instead, it builds up in the blood and hyperphosphataemia develops.
This guideline was previously called hyperphosphataemia in chronic kidney disease: management of hyperphosphataemia in patients with stage 4 or 5 chronic kidney disease.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.